Fulcrum therapeutics announces recent business highlights and financial results for second quarter 2024

― on track to report topline data for phase 3 reach trial of losmapimod in facioscapulohumeral muscular dystrophy (fshd) by the end of october 2024 ―

FULC Ratings Summary

FULC Quant Ranking